menu
    • menu
    [{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Mylan"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ PRA Health Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ PRA Health Sciences"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"MHC class II gene","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"HLA-DRB1","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"MHC class II gene","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mapi Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kinimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kinimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinimmune \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Mapi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Glatiramer Acetate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Viatris \/ Mapi Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Mapi Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Glatiramer Acetate

    Menu

    Glatiramer Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Viatris

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Mapi Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment ...

                            Details : Copaxone Depot, a long-acting glatiramer acetate designed to be administered as an intramuscular injection, is being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS).

                            Brand Name : WhisperJECT

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 07, 2023

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Mapi Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kinimmune

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kinimmune

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinimmune Publishes Results from A Phase I “Window of Opportunity” Trial in Patients with Solid Tumors

                            Details : Copaxone (glatiramer acetate) its ability to induce the peripheral Th2 cells and their subsequent crossing of the blood barrier allows for the reduction of further inflammation within the CNS.

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 03, 2023

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing Forms of Multiple ...

                            Details : The study evaluating a long-acting glatiramer acetate (copaxone) injection, GA Depot 40 mg once every four weeks, met the primary endpoint, significantly reducing the annualized relapse rate (ARR) by 30.1 percent compared to placebo.

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 21, 2022

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma to Present Posters on GA Depot for Treating Relapsing Forms of Multiple Sclerosis (MS) and Primary...

                            Details : At AAN, company will be presenting 5 year data from Phase IIa study in RRMS. Also, the results seeN in the ongoing Phase II study for GA Depot in primary progressive MS (PPMS) patients, to be presented at the meeting as plan to initiate a Phase-3 for PPM...

                            Brand Name : GA Depot

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressi...

                            Details : GA Depot is a long-acting injection version of the approved Copaxone® (Glatiramer Acetate) designed to be administered as an intramuscular injection once every four weeks, is being evaluated for treatment of relapsing forms of multiple sclerosis.

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2022

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Teva Pharmaceutical Industries

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            COPAXONE® Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

                            Details : The label update of COPAXONE® (Glatiramer Acetate) follows the review of clinical and non-clinical evidence, including latest data from the COBRA study that investigated safety outcomes in infants breastfed by mothers with MS undergoing GA treatment dur...

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 10, 2022

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Teva Pharmaceutical Industries

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Safety Data on Treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relap...

                            Details : Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (COPAXONE® 20 or 40 mg/mL) or breastfeeding under no DMT treatment.

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 13, 2021

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Teva Pharmaceutical Industries

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Teva Pharmaceutical Industries

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Safety Data on Treatment of Breastfeeding Mothers with COPAXONE® (glatiramer acetate) Who Are Living with...

                            Details : A non-interventional analysis of the study found no evidence of safety concerns in infants born to mothers with multiple sclerosis (MS) who were breastfeeding and receiving glatiramer acetate (GA) treatment.

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2021

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : PRA Health Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Engages PRA Health Sciences as CRO for Phase III Multiple Sclerosis Trial

                            Details : GA Depot is a long-acting version of Teva Pharmaceutical’s Copaxone (glatiramer acetate). Mapi Pharma is working with the CRO PRA Health Sciences for its Phase III trial investigating glatiramer acetate depot (GA Depot) for relapsing forms of multiple ...

                            Brand Name : Copaxone

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 20, 2021

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : PRA Health Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed

                            Mapi Pharma

                            Israel arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial

                            Details : GA Depot is a long acting injection version of the approved Glatiramer Acetate products (Copaxone® and its generic versions) for treating multiple sclerosis (RMS), designed to be administered as an intramuscular injection once every four weeks.

                            Brand Name : GA Depot

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 21, 2020

                            Lead Product(s) : Glatiramer Acetate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth